Zydus Lifesciences and RK Pharma enter into exclusive licensing and commercialization agreement

By Reuters

Zydus Lifesciences and RK Pharma enter into exclusive licensing and commercialization agreement

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Previous articleNext article

POPULAR CATEGORY

misc

16610

entertainment

18212

corporate

15295

research

9180

wellness

15014

athletics

19077